drugset / Trial / NCT06774963
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
RandomizedSequentialOpen-labelTreatment
Summary
This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors.
Timeline
- Start
- 2025-01-07
- Primary completion
- 2026-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LNCB74 | Other / unclassified | — | Intravenous |